Research programme: interleukin-4 therapeutics - Medicenna Therapeutics

Drug Profile

Research programme: interleukin-4 therapeutics - Medicenna Therapeutics

Alternative Names: IL4-ECs; Interleukin-4 Empowered Cytokines™; MDNA 56; MDNA-57

Latest Information Update: 06 Mar 2017

Price : $50

At a glance

  • Originator Medicenna Therapeutics
  • Class Antineoplastics; Immunotoxins; Recombinant fusion proteins
  • Mechanism of Action Apoptosis stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Haematological malignancies; Solid tumours

Most Recent Events

  • 02 Mar 2017 Medicenna Therapeutics Inc. has been acquired by Medicenna Therapeutics Corp
  • 20 Sep 2016 Early research in Haematological malignancies in USA (unspecified route)
  • 20 Sep 2016 Early research in Solid tumours in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top